NeoVirTech SAS, a biotechnology company developing autofluorescent viruses to decipher viral infection in vivo and to detect and measure antiviral activities started a collaboration with Transgene SA, a biopharmaceutical company focused on discovering and developing targeted immunotherapies for the treatment of cancer and infectious diseases. Combination of NeoVirTech’s technology with Transgene products provides an unprecedented way to understand and control viral infection directly using microscopy imaging.
NeoVirTech is awarded at the National contest for innovative companies (ILab) organized by BPI France and the French Ministry. The ANTIPOX project founded by this prestigious price will aim at developing new antivirals against the Poxvirus family. contact us for more information !
NeoVirTech sponsors the XXII IRT on nucleosides, nucleotides and nucleic acids that will be held at Institut Pasteur (Paris) in July 2016. A large part of this meeting focuses on antiviral drug discovery and screening. NeoVirTech will present its offer to all participants. Flyer will be available soon, keep in touch via our RSS feed.
In collaboration with Dr. Anne-Françoise Tilkin Mariamé (INSERM/Toulouse) and INSERM-Transfert, NeoVirTech deposit a patent protection of a repositioned molecule for the treatment of metastatic melanoma. This FDA approved molecule was discovered during a screening campaign managed by NeoVirTech.
NeoVirTech collaborates with an undisclosed large pharmaceutical company to develop a specific class of autofluorescent viruses.